Warnex offers KRAS test for colorectal cancer
This article was originally published in Clinica
Warnex has become the latest firm to offer KRAS gene testing for patients with colorectal cancer, through its Medical Laboratories division. The Quebec, Canada company joins DxS (Manchester, UK) and Clarient (Aliso Viejo, California), which already carry out KRAS testing. KRAS mutations, which occur in around 40% of colorectal cancer patients, are associated with a poor response to EGFR inhibitors, such as Amgen's Vectibix and Merck KGaA's Erbitux. Vectibix is only approved in the EU for patients with a non-mutated KRAS gene, but US labelling does not mention KRAS. However, earlier this month, the American Society of Clinical Oncology released a provisional clinical opinion recommending KRAS testing in patients with metastatic colorectal cancer.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.